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ABSTRACT
Introduction: Potentially preventable hospitalisation
(PPH) has been adopted widely by international health
systems as an indicator of the accessibility and overall
effectiveness of primary care. The Assessing
Preventable Hospitalisation InDicators (APHID) study
will validate PPH as a measure of health system
performance in Australia and Scotland. APHID will be
the first large-scale study internationally to explore
longitudinal relationships between primary care and
PPH using detailed person-level information about
health risk factors, health status and health service use.
Methods and analysis: APHID will create a new
longitudinal data resource by linking together data from
a large-scale cohort study (the 45 and Up Study) and
prospective administrative data relating to use of general
practitioner (GP) services, dispensing of
pharmaceuticals, emergency department presentations,
hospital admissions and deaths. We will use these
linked person-level data to explore relationships
between frequency, volume, nature and costs of primary
care services, hospital admissions for PPH diagnoses,
and health outcomes, and factors that confound and
mediate these relationships. Using multilevel modelling
techniques, we will quantify the contributions of
person-level, geographic-level and service-level factors
to variation in PPH rates, including socioeconomic
status, country of birth, geographic remoteness,
physical and mental health status, availability of GP and
other services, and hospital characteristics.
Ethics and dissemination: Participants have
consented to use of their questionnaire data and to data
linkage. Ethical approval has been obtained for the
study. Dissemination mechanisms include engagement
of policy stakeholders through a reference group and
policy forum, and production of summary reports for
policy audiences in parallel with the scientific papers
from the study.
INTRODUCTION
Potentially preventable hospitalisations
(PPH) (also termed as hospitalisations for
‘ambulatory care sensitive conditions’
(ACSC), ‘ambulatory sensitive hospitalisa-
tions’ and ‘preventable hospitalisations’) are
those that could potentially be prevented by
timely and effective provision of primary
care,1 The concept of PPHs was originally
developed in the USA,1–4 but has been
adopted widely by international health
ARTICLE SUMMARY
Article focus
▪ This article reports the protocol for the
Assessing Preventable Hospitalisation InDicators
(APHID) study.
▪ APHID will validate potentially preventable hospi-
talisations (PPH) as a measure of health system
performance in Australia and Scotland.
▪ APHID will create a new longitudinal data
resource by linking together detailed data from a
large-scale cohort study and prospective adminis-
trative data relating to the use of health services.
Key messages
▪ PPH have been adopted widely by international
health systems as an indicator of the accessibility
and overall effectiveness of primary care.
▪ However, much of the existing evidence is based
on ecological (aggregate) analyses, and comes
from the USA.
▪ Key questions about the validity and value of
PPH measures, and their applicability in different
settings, remain unanswered.
Strengths and limitations of this study
▪ APHID will be the first large-scale study inter-
nationally to explore longitudinal relationships
between primary care and PPH using detailed
person-level information about health risk
factors, health status and health service use.
▪ Limitations include the use of administrative
claims data containing only limited information
about the quality of primary care services, and
reliance on self-reported data for some predictor
variables.
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systems as an indicator of the accessibility and overall
effectiveness of primary care.5–8 In Australia, rates of
PPH for selected conditions are a key performance indi-
cator speciﬁed in the National Healthcare Agreement
(NHA),9 10 which is intended to track progress against
the objective ‘Australians receive appropriate high
quality and affordable primary and community health
services’. The conditions that are currently included in
the NHA indicator are shown in table 1.10 These are
based on the Victorian ACSC study,11 which in turn had
its origins in work in the USA in the 1990s1–3 that used
physician expert panels to identify and rank candidate
conditions. However, there is considerable variation in
the PPH condition sets that are used across countries,
and for PPH measures are particularly attractive as indi-
cators of health system performance because they can
be generated from routine hospital data and yet focus
attention on the outcomes of care, rather than process
or throughput. However, a number of key questions
about the validity and value of these measures remain
unanswered.
Much of the research relating to PPHs has focused on
socioeconomic, race and urban-rural differentials, which
may reﬂect gradients in health status (disease prevalence
and severity) as well as in access to or quality of health-
care. However, studies in the USA, mainly using eco-
logical (correlational) approaches (ie, the unit of
analysis was an aggregate of individuals, usually the
population of a geographic area), have also focused on
the association between PPHs and the nature of the
healthcare system, reporting that self-reported access to
medical care,12 increased physician supply13–18 and pres-
ence of community and rural health centres19–21 are
inversely correlated with PPH rates, while high rates of
emergency department (ED) attendances are positively
associated with PPH rates.21
Evidence from other settings is sparse. A recent study
in the UK, limited to chronic obstructive pulmonary
disease (COPD) and using an ecological design, found
that patient-reported access to consultation within 2 days,
and primary care stafﬁng, were protective for admission
rates.22 The only Australian study to date,23 again using
ecological methods, found that access to medical care
and rate of general practitioner (GP) visits (both self-
reported) and GP supply were negatively associated with
PPH rates in Primary Care Partnership areas in the state
of Victoria, independent of disease prevalence. However,
these associations disappeared when rural residence was
taken into account. The authors concluded that rural
residence may be a greater risk factor for PPH than
access to primary care, but did not identify the potential
role of the hospital (eg, variability in admission practices,
availability of beds) in driving urban–rural differences in
PPH. Indeed, PPH rates are potentially an indicator of
access to hospital care, as well as to primary care, an issue
that to our knowledge has never been investigated, either
in Australia or internationally.
The Assessing Preventable Hospitalisation InDicators
(APHID) project will validate PPH as a measure of
health system performance in Australia and Scotland. It
involves three partner agencies with key roles in using
these measures to drive change in the Australian health
system: the Australian Commission on Safety and Quality
in Health Care, the Agency for Clinical Innovation and
the NSW Bureau of Health Information.
Using linked person-level data, the APHID project will
explore relationships between frequency, volume, nature
and costs of primary care services, hospital admissions
for PPH diagnoses, and health outcomes, and factors
that confound and mediate these relationships. Using
multilevel modelling techniques, we will quantify the
contributions of person-level, geographic-level and
service-level factors to variation in PPH rates, including
socioeconomic status, country of birth, geographic
remoteness, physical and mental health status, availabil-
ity of GP and other services, and hospital characteristics.
The use of individual data and taking account of the dif-
ferent levels that may inﬂuence outcomes means that we
will avoid the risk of the ecological fallacy common in
ecological studies.24
Our speciﬁc objectives are:
1. To link questionnaire data from 267 000 participants
in the 45 and Up Study to prospective data on use of
primary care services, ED presentations, hospitalisa-
tions and deaths.
2. To analyse these linked data to establish the relation-
ships between use of primary care services and
Table 1 Conditions included in the Australian National
Healthcare Agreement potentially preventable
hospitalisations performance indicator
Vaccine-preventable
conditions
Influenza and pneumonia
Other vaccine-preventable
conditions
Acute conditions Dehydration and
gastroenteritis
Pyelonephritis
Perforated/bleeding ulcer
Cellulitis
Pelvic inflammatory disease
Ear, nose and throat
infections
Dental conditions
Appendicitis with generalised
peritonitis
Chronic conditions Asthma
Congestive cardiac failure
Diabetes complications
Chronic obstructive pulmonary
disease
Angina
Iron deficiency anaemia
Hypertension
Nutritional deficiencies
Rheumatic heart disease
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measures of PPH, and the contributions of person-
level, geographic-level and service-level factors to
these relationships.
3. To analyse these linked data to establish the relation-
ship between PPH and health outcomes for people
with chronic conditions, and the contributions of
person-level, geographic-level and service-level factors
to these relationships.
4. To conduct comparative analyses using data from the
Scottish Morbidity Records.
5. To consider, synthesis and effectively communicate
these ﬁndings in order to drive change.
METHODS AND ANALYSIS
Data sources
The 45 and Up Study25 is a cohort study of 267 000 men
and women aged 45 years and over and resident in
New South Wales (NSW), Australia’s largest state. Brieﬂy,
participants were randomly sampled from the Medicare
Australia database and joined the Study by completing a
mailed self-administered questionnaire (available at
http://www.45andup.org.au/) and providing consent
for long-term follow-up, including linkage to health
records. People resident in non-urban areas and those
aged 80 and over were oversampled. Recruitment
occurred from February 2006 to April 2009. The overall
response rate is estimated at 18%, consistent with similar
cohort studies.
Data captured in the 45 and Up Study baseline and
follow-up questionnaires include the following self-
reported chronic conditions that are relevant to PPH:
(ever diagnosed) heart disease, high blood pressure,
diabetes and asthma; and (treated in the last month)
‘other’ heart conditions, high blood pressure and
asthma. Additional data coded from free text ﬁelds allow
identiﬁcation of participants who reported angina, con-
gestive heart failure and COPD.
Questionnaire data also include information on key
potential confounders and mediating factors, including
age, sex, household income, level of education, smoking
history, alcohol use, physical activity (Active Australia
questionnaire),26 height and weight, functional status
(Medical Outcomes Study Physical Functioning scale),27
psychological distress (Kessler 10 scale)28 and medical
and surgical history.
The NSW Admitted Patient Data Collection (APDC)
will be used to identify PPH admissions and to provide
information for risk-adjustment (comorbidities, previous
admissions). The APDC includes records for all separa-
tions (discharges, transfers and deaths) from all NSW
public and private sector hospitals and day procedure
centres. The information reported includes patient
demographics, source of referral to the service, service
referred to on separation and diagnoses, procedures and
external causes of injury coded according to the
Australian modiﬁcation of the International Statistical
Classiﬁcation of Diseases and Related Problems, 10th
revision (ICD-10-AM).29 Audits have shown good-to-excel-
lent coding of diagnoses and procedures in Australian
hospital data.30 Because the APDC contains information
on episodes of care (ending with the discharge, transfer
or death of a patient), rather than periods of stay in hos-
pital, a continuous period of stay will be constructed by
combining all contiguous episodes of care, including
nested and non-nested transfers, for the same patient.
The NSW Emergency Department Data Collection
(EDDC) will provide information about ED presenta-
tions. The EDDC covers 80 EDs, including all those in
public hospitals in the Sydney metropolitan area, and
captures about 75% of all presentations to NSW EDs.
The information reported includes patient demograph-
ics, mode of arrival, triage category, mode of separation,
service referred to on separation, diagnoses and
procedures.
NSW Registry of Births, Death and Marriages (RBDM)
death registration (fact-of-death) data will be used to
ascertain deaths following hospitalisation and for censor-
ing in person-time analyses. Most deaths are registered
within 4 weeks of the date of death.
Most non-hospital medical care in Australia is provided
on a fee for service basis, paid by the universal health
insurance scheme, Medicare, according to the Medical
Beneﬁts Schedule (MBS) of payments. We will use MBS
claims data to measure use of GP, specialist and other
Medicare-funded services. For each claim for service pro-
cessed, the MBS claims data include the date of the
service, the item number for the service, patient age,
gender and postcode, provider business code, the
amount charged by the provider, the Medicare beneﬁt
for the service, the method of payment and de-identiﬁed
information relating to the provider. Individual providers
who practice in more than one location can have mul-
tiple Medicare provider numbers. GP claims for patient
care under MBS distinguish brief, standard, long and pro-
longed consultations.
Under the Pharmaceutical Beneﬁts Scheme (PBS),
the Australian government subsidises the cost of medi-
cine for most medical conditions for all Australian resi-
dents who hold a current Medicare card. We will use
PBS claims data to measure use of medications and
medication compliance. Only pharmaceuticals that
qualify for subsidy are included in PBS claims data,
coded to the Pharmaceutical Beneﬁts Schedule. PBS
data include PBS item number, date, type of prescrip-
tion, PBS payment category, specialty of provider and
pharmacist’s business postcode.
Data linkage
Linkage of MBS and PBS data to 45 and Up Study data
will be performed by the Sax Institute. All 45 and Up
Study participants consented speciﬁcally to this linkage,
and it is performed under approvals from the Australian
Government Department of Human Services and the
Australian Government Department of Health and
Ageing ethics committee. This will be a direct
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(deterministic) linkage, using an encrypted version of
the Medicare number. All other linkages will be under-
taken by the Centre for Health Record Linkage
(CHeReL), which links questionnaire data from the 45
and Up Study to the other databases that will be used in
this study on an ongoing basis.
The CHeReL uses probabilistic record linkage techni-
ques to link personal identiﬁers (including full name,
date of birth, sex and address) from records in these
datasets. Evaluation of the accuracy of the linkage is
determined by clerical review of samples of matched
records. Quality assurance data show false positive and
negative rates of 0.4% and <0.1%, respectively. The
CHeReL uses the ‘best practice protocol’31 for preserv-
ing individual privacy. The data custodians will supply
de-identiﬁed datasets for each of the data sources to the
researchers, who will then merge the records together
using a unique identiﬁer.
The linked data will include all records available from
July 2000 onwards for each dataset. This will provide
retrospective data for risk-adjustment, as well as prospect-
ive data for ascertainment of incident events.
Analysis plan
To establish the relationships between use of Medicare-
funded services and measures of PPH (objective 2), a
series of multilevel models will be built using prospective
data for all participants in the 45 and Up Study.
Follow-up will be to the end of the period for which
APDC data are available (December 2011), or death,
whichever comes ﬁrst, giving a duration of follow-up
from 2 to 4 years depending on the date of recruitment
into the 45 and Up Study. Model building will be an
iterative process and models will have up to six levels:
individuals (n=267 000), GP providers (n=14 500),
Divisions of GP or Medicare Locals (n=20); Statistical
Local Areas (SLAs, n=250), hospitals (n=400) and Local
Health Districts (LHDs, n=18).
Analyses to explore the relationship between PPH and
health outcomes for people with chronic conditions
(objective 3) will be restricted to 45 and Up Study parti-
cipants who self-reported chronic PPH conditions
(asthma, angina, congestive heart failure, COPD, dia-
betes and hypertension) at baseline. They will compare
outcomes for people with these conditions who have
PPH episodes during follow-up with those who do not.
Analyses will be performed for all the chronic conditions
as a group and stratiﬁed according to individual condi-
tion, where numbers support this. Again, a series of
multilevel models will be built, with up to six levels: indi-
viduals (n=126 000), GP providers (n=14 000), Medicare
Locals (n=20); SLAs (n=250), hospitals (n=400) and
LHDs (n=18).
Outcome measures related to PPH will include: time to
ﬁrst PPH episode; number of PPH episodes; total PPH
inpatient bed days; average length of PPH hospital stay;
estimated costs of PPH episodes to the health system and
the individual. Hospital costs will be estimated using
Australian Reﬁned Diagnosis Related Group (AR-DRG)
costs obtained from national public and private sector
cost data.32 Costs to the individual will be estimated using
information on labour force status and household
income. Analyses will be performed for all causes and
stratiﬁed according to vaccine-preventable, chronic and
acute PPH, and individual PPH diagnoses where
numbers support this.
Health outcomes will include: time to death; number
of non-PPH hospital stays; total bed days for non-PPH
hospital stays; number of ED presentations; number of
MBS services; cost of hospital services; cost of MBS ser-
vices (beneﬁt paid and out-of-pocket costs); cost of PBS
services; estimated costs to the health system and to
individuals.
Individual-level predictor variables will include:
Demographic and socioeconomic factors: age, sex, country
of birth, language spoken at home, indigenous status
(note small numbers will preclude Indigenous-speciﬁc
reporting), accessibility and remoteness (using the
Accessibility/Remoteness Index of Australia (ARIA+)
which assigns scores to geographic areas based on the
road distance to service towns of different sizes33),
private health insurance and healthcare card holder
status, household income, highest level of education,
employment status and household composition.
Use of Medicare-funded services: number of GP consulta-
tions (brief, standard, long and prolonged), proportion
of consultations that are long or prolonged, MBS bene-
ﬁts and out-of-pocket costs and PBS beneﬁts and
out-of-pocket costs.
Quality of GP care: number of GP providers providing
care; usual provider continuity index (proportion of visits
to most frequently seen GP provider); continuity of care
index (derived from number of different GP providers
seen and number of visits to each GP provider)34; claims
for GP Management Plan or Team Care Arrangement
(chronic conditions only); completion of annual cycle of
care (diabetes only); multidisciplinary diabetes care, that
is, participants saw a GP and at least one of the following:
specialist, practice nurse, diabetes educator, dietician and
ophthalmologist/optometrist (diabetes only); medica-
tion compliance (persistence of dispensing).
ED presentations: number of ED presentations. These
analyses will be restricted to participants resident in
SLAs serviced by EDs that are captured in the EDDC.
Health risk factors: smoking status, alcohol intake, phys-
ical activity, body mass index, hypertension and high
blood cholesterol.
Health status: self-reported functional status, psycho-
logical distress, social support, number and type of self-
reported chronic conditions, use of hospital and ED ser-
vices in 5 years prior to baseline and pattern and volume
of the use of Medicare-funded services in 5 years prior
to baseline.
GP provider-level predictor variables will include: voca-
tional registration; number of 45 and Up Study partici-
pants using this provider, annual number of
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consultations (brief, standard, long and prolonged); pro-
portion of consultations that are long or prolonged.
Medicare Local-level predictor variables will include:
presence of active Primary Care Collaboratives pro-
gramme or active chronic disease management pro-
gramme; proportion of local GPs who are participating
in Medicare Locals.
SLA-level predictor variables will include: accessibility
(ARIA+),33 socioeconomic status (using Socio Economic
Status for Areas (SEIFA) indexes, four indexes that sum-
marise different aspects of the socioeconomic conditions
of people living in an area based upon sets of social and
economic information from the Australian Census35);
full-time equivalent GPs; medical workers, nurses, phar-
macists, Aboriginal health workers and community ser-
vices workers per 10 000 population; rates of
unemployment and labour force participation.
Hospital-level predictor variables will include: accessi-
bility (ARIA+)33; number of beds; peer group; number
of admissions (emergency, planned and medical surgi-
cal); measures of casemix; patient experience survey
data; measures of hospital workforce.
LHD-level predictor variables will include: number of
hospitals and community-based services; measures of
LHD workforce.
Statistical analysis will be performed using MLwiN36
and SAS.37 Cross-classiﬁed multilevel models will be
used to account for the non-nested hierarchies of, for
example, GP provider, the hospital attended and the
SLA of residence38 and will be estimated using Markov
Chain Monte Carlo methods in MLwiN. Time to ﬁrst
PPH episode will be modelled using multilevel Cox
(proportional hazards) regression analysis. All other out-
comes will be modelled using multilevel Poisson regres-
sion, applying transformations to continuous variables as
appropriate. All models will be corrected for possible
overdispersion, either by using an adjustment parameter
in the Poisson model or by ﬁtting a negative binomial
regression model. In the case of a highly right skewed
distribution of the number of admissions beyond the
ﬁrst, zero-inﬂated Poisson or multinomial models will be
ﬁtted. For all models, squared and cubed terms of con-
tinuous predictor variables will be tested to improve the
model ﬁt. A method of fractional polynomials for con-
tinuous predictor variables will be used where
appropriate.
Statistical power
Table 2 gives information on the projected numbers of
PPH episodes, and persons experiencing PPH episodes,
that will be available for analysis, based on linked data
for the 45 and Up Study to date, and taking into
account delays in the availability of data. Around
950 000 person-years of follow-up will be available for
analysis. With the sample size available, we will be able
to estimate average length of stay and inpatient costs,
respectively, with a precision of 0.7 days and $650 for
low-prevalence PPH conditions (eg, rheumatic heart
disease, pelvic inﬂammatory disease); 0.3 days and $275
for mid-prevalence PPH (asthma, inﬂuenza and cellu-
litis) and 0.07 days and $65 for high-prevalence PPH
(diabetes complications).
Table 3 presents minimum detectable ratios for com-
parisons of mean length of stay and hospital costs for
people with self-reported chronic conditions who do
and do not have a PPH episode during follow-up
Table 3 Minimum detectable mean ratios* for analyses investigating the relationship between potentially preventable
hospitalisations and health outcomes for people with chronic conditions, Assessing Preventable Hospitalisation InDicators
(APHID) study
Outcome
Self-reported chronic condition
Hypertension Asthma Diabetes Angina
Mean length of stay 0.97 1.03 0.96 1.05 0.96 1.04 0.95 1.05
Mean hospital cost 0.98 1.02 0.97 1.03 0.97 1.03 0.95 1.04
*5% significance, 80% power.
Table 2 Projected* numbers of potentially preventable
hospitalisation (PPH) episodes and persons experiencing
PPH episodes, Assessing Preventable Hospitalisation
InDicators (APHID) study
Condition Episodes Persons
Chronic 22440 13000
Asthma 650 480
Congestive cardiac failure 2500 1870
Diabetes complications 11400 7000
Chronic obstructive pulmonary
disease
4100 2400
Angina 1850 1600
Iron deficiency anaemia 1400 1100
Other chronic 540 480
Vaccine-preventable 620 550
Influenza and pneumonia 500 450
Other vaccine-preventable 120 100
Acute 7350 7400
Dehydration and gastroenteritis 2300 2050
Pyelonephritis 2100 1750
Dental conditions 970 930
Other acute 1980 1592
All conditions 30 410 19 850
*Projections are based on linked data for the 45 and Up Study
from study entry up to December 2010, and assume that similar
age-specific event rates will apply for the period from study entry
up to December 2011.
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(objective 3). The power of the study will be monitored
during the model-building process, using sample size
calculators speciﬁcally developed for multilevel models
(PinT).39 These require estimates of variances and covar-
iances for predictor variables and random effects that
are not available from the literature.
Comparative analyses using Scottish hospital data
It is intended to undertake comparative analysis using
Scottish data. This part of the project is at earlier stage
of development and the detailed research is still subject
to funding and approval. Scotland offers an interesting
comparator to Australia. Both countries contain large
areas that are remote and inaccessible: 6% of the
Scottish population live on areas classiﬁed as remote
and rural while in Australia 10% live in areas classiﬁed
as remote or very remote.40 41 Both countries face the
challenges of providing healthcare in these areas.
However, while in Australia health is poorer in rural
areas than in urban areas, in Scotland the opposite
holds42 and this is also true for deprivation.41 43 44
Comparative analysis offers the prospect of distinguish-
ing the contributions of socioeconomic status, health
status and rurality and remoteness to geographic vari-
ation in rates of PPHs.
GP supply has been reported to be negatively asso-
ciated with PPH rates in Australia.11 Scotland has consid-
erably fewer GPs per 100 000 population than does
Australia: 8145 and 110,46 respectively. Patients are regis-
tered with a speciﬁc practice in Scotland but not in
Australia, and this may signiﬁcantly alter organisational
approaches to preventative healthcare. A further differ-
ence between the two countries is the funding of health-
care: in Australia 45%47 of the population holds private
health insurance, compared with only 11%48 of the
Scottish population.
Scottish morbidity records will be used to identify
rates of PPHs across Scotland. Factors to be explored
include quality of primary care, the availability of
primary and secondary care, the rurality and remoteness
of the population, the degree of deprivation and popula-
tion characteristics including age, gender and ethnicity.
The empirical strategy outlined above to analyse the
Australian data will be employed and comparative ana-
lysis will be undertaken. Wherever possible, this will
employ a common speciﬁcation in order to distinguish
the differential impact of the factors and the extent to
which these might be explained by differences in under-
lying population behaviours and health delivery systems.
A strength of the Scottish analysis is that relatively
robust measures of the quality of primary care can be
constructed. In 2004, the Quality and Outcome
Framework (QOF) was introduced to incentivise the
quality of care provided by general practices. Practices
could accumulate points on 146 indicators and receive
payment according to the number of points achieved.
For our analyses, measures of the quality of chronic
disease management will be constructed using the
practices’ performance on the clinical indicators within
QOF, such as for example percentage of patients with
asthma who had an asthma review in the preceding
15 months49 and investigate whether these measures are
associated with PPH rates.
Ethics and dissemination
Participants have consented to use of their questionnaire
data and to data linkage. Ethical approval has been
obtained from the NSW Population and Health Services
Ethics Committee, the Aboriginal Health and Medical
Research Council of NSW Ethics Committee and the
University of Western Sydney Ethics Committee.
Dissemination mechanisms include engagement of
policy stakeholders through a reference group and
policy forum, which will use deliberative dialogue50
approaches, with the goal being to identify potential
actions and key implementation considerations.
We will write summary reports in formats designed for
policy audiences in parallel with the scientiﬁc papers
from the study. Our experience indicates that doing this
enhances the clarity and quality of the scientiﬁc papers
as well as facilitating quick uptake of the research ﬁnd-
ings. The summaries for policy will focus on incorporat-
ing the ﬁndings with other relevant evidence into
compelling accounts that highlight potential actions.51
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